# US 2022/0031616 A1 · Aerosolized CBD Liposomes for the treatment of Asthma and other pulmonary inflammatory disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031616 A1
- Document ID: US20220031616A1
- Status: Published application
- Kind: A1
- Application number: 17/389,302
- Filed: 2021-07-29
- Published: 2022-02-03
- Earliest claimed: 2020-07-29
- Inventors: Matthew Halpert; John Hartenbach
- Web page: https://patentgrep.com/patent/US20220031616A1

## CPC

- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to the new compounds and improved treatment regimens that are effective in treating patients and minimizing the negative side effects previously associated with pulmonary care and treatment. Specifically, liposomal cannabinoids with or without other known treatments are used to provide a more effective and safer treatment for Asthma and/or pulmonary inflammation disorders or conditions in a diverse population.

## Claims

### Claim 1

A method for treating pulmonary inflammation disorders or conditions comprising a therapeutically effective amount of one or more endocannabinoids in a liposomal encapsulation.

### Claim 2 (depends on 1)

The method of claim 1 wherein the one or more endocannabinoids is selected from CBD, delta 8 THC, delta 9 THC, CBG, CBN and CBV.

### Claim 3 (depends on 2)

The method of claim 2 wherein one of the endocannabinoids is CBD.

### Claim 4

A cannabinoid liposome formulation comprising: a liposome carrier and one or more cannabinoids in a formulation.

### Claim 5 (depends on 1)

The method of claim 1 further comprising co-administering or co-formulating with one or more steroids, biologics, natural agents and NSAIDs with or without their own carrier or encapsulation formulations.
